Home Meetings Highlights

Highlights

Summaries and high points from meetings about lung cancer and other thoracic neoplasms.

Latest

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

lungcanc

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib

PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC

Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy

Single-Agent Pembrolizumab Active Against STK11– and KEAP1– Mutated NSCLC According to KEYNOTE-042 Analysis

IASLC Workshop in Lung Cancer Clinical Research

lungcanc

ELCC 2017 Unveils New Research Regarding Screening, Immunotherapy, Treatment Planning, and...

lungcanc

Best of the IASLC 17th World Conference on Lung Cancer in...

lungcanc

IASLC Small Cell Lung Cancer Workshop

lungcanc

17th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting

lungcanc

First Congress of Interventional Pulmonology & EBUS and the XI South...

lungcanc

Highlights from IASLC WCLC 2016

lungcanc

Honoring Superb Advocacy at the 13th Annual Prevent Cancer Quantitative Imaging...

lungcanc

IASLC and APLCC Present 7th IASLC Asia Pacific Lung Cancer Conference

lungcanc

WCLC 2016 Together Against Lung Cancer

lungcanc

1 234 Page 3 of 4

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib